[시장보고서]세계의 의약품 무균 시험 시장 규모 및 점유율 분석 : 유형별, 제품 유형별, 시험 유형별, 용도별, 최종사용자별

세계의 의약품 무균 시험 시장 규모 및 점유율 분석 : 유형별, 제품 유형별, 시험 유형별, 용도별, 최종사용자별 - 산업 수요 예측(-2030년)

Pharmaceutical Sterility Testing Market Size and Share Analysis Report by Type, Product Type, Test Type, Application, End User - Global Industry Demand Forecast to 2030

상품코드 : 1337630

리서치사 : Prescient & Strategic Intelligence Private Limited

발행일 : 2023년 08월

페이지 정보 : 영문 190 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,900

￦ 6,810,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 불가능합니다.

US $ 6,400

￦ 8,894,000

Printable PDF (Group User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,400

￦ 11,674,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업 및 자회사의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 의약품 무균 시험 시장 규모는 2030년까지 29억 5,390만 달러에 달할 것으로 예상되며, 2023-2030년 성장률은 11.2%에 달할 것으로 예상됩니다. 이는 생명공학 및 제약 기업의 발전, 연구 개발 활동의 증가, 질병 발생률 증가, 의료 산업에 대한 정부의 막대한 지출에 기인합니다.

해충으로 인한 질병 발생이 증가함에 따라 효과적이고 안전한 치료제를 생산하기 위한 연구개발 활동이 증가하고 있습니다. 또한, COVID-19와 같은 심각한 바이러스 감염증을 예방하기 위한 연구와 효과적이고 안전한 백신 개발을 중심으로 한 연구가 계속되고 있는 것도 산업에 긍정적인 영향을 미치고 있습니다.

혈액 악성종양 발생이 증가하고 있으며, Leukemia & Lymphoma Society에 따르면 미국에서는 3명 중 1명이 백혈병, 골수종, 림프종에 걸렸다고 합니다. 유전자 치료와 면역세포 치료와 같은 바이오의약품은 혈액암의 대체 치료법으로 빠르게 받아들여지고 있습니다. 이는 이러한 치료제가 이러한 종류의 질병에 대해 높은 효능과 효능을 가지고 있기 때문입니다.

2022년까지 아웃소싱 부문이 60%의 점유율로 업계를 주도할 것으로 예상됩니다. 이는 아웃소싱이 중소규모의 제약회사에 유리하기 때문에 널리 보급되고 있기 때문입니다.

또한, 아웃소싱은 제약회사에게 치료 전문성과 업무 효율성을 높이고, 온디맨드 서비스를 쉽게 이용할 수 있으며, 지리적 입지를 향상시키는 데 도움이 됩니다.

또한, 많은 중소기업은 양질의 무균 시험 요건을 충족시킬 수 있는 충분한 자원이 없기 때문에 FDA의 규정을 통과하기 위해 아웃소싱을 요구하고 있습니다.

북미 시장은 2022년 40%의 큰 점유율을 차지했습니다. 이는 주요 제약 및 바이오 제약 기업의 존재, 생명공학 산업 및 제약 산업의 R&D 활동 증가, 제품 도입 증가, 만성 질환의 높은 발생률, R&D 시설 설립에 대한 정부 지원 정책 등이 원인으로 꼽힙니다.

또한 강력한 의료 정책의 존재, 엄격한 의약품 승인 필요성, 의약품 안전에 대한 일반 대중의 인식 증가, 첨단 기술 수용 증가, 여러 종류의 혈액 악성 종양 치료를 위한 유전자 치료 및 세포 치료 출시 등이 이 지역의 산업 발전에 기여하고 있습니다.

또한 유럽은 북미에 이어 두 번째로 높은 매출 점유율을 보이고 있습니다. 이는 이 지역의 많은 국가에서 보편적 의료보험제도가 형성되어 의료제품에 대한 수요가 크게 증가했기 때문입니다. 의약품 안전에 대한 엄격한 규제 정책을 채택하는 것도 산업 성장에 기여하는 주요 요인입니다.

디지털 플랫폼의 수용 확대는 의약품 무균 시험 수요에 긍정적인 영향을 미치고 있으며, 이러한 추세는 향후 몇 년 동안 지속될 것으로 보입니다.

이 보고서는 세계 의약품 무균 시험 시장에 대한 조사 분석과 함께 시장 역학, 지역별 시장 매출, 경쟁 상황 등의 정보를 제공합니다.

Steris plc
Boston Analytical
Sartorius AG
Arbro Pharmaceuticals Private Limited & Auriga Research Private Limited
Lucideon Limited
Pace Analytical Life Sciences, LLC
SGS SA
Sotera Health Company
Merck KGaA
Pall Corporation
Charles River Laboratories International, Inc
Thermo Fisher Scientific Inc
Almac Group Limited
Pacific BioLabs
BIOMERIEUX S.A.

제32장 부록

ksm

영문 목차

영문목차

The pharmaceutical sterility testing market will reach USD 2,953.9 million by 2030, growing at a rate of 11.2% during 2023-2030. This is because of the development of biotech and pharma firms, an increase in their R&D activities, an increase in the incidence of diseases, and substantial government spending on the healthcare industry.

The increasing occurrence of diseases in the pest has brought about an increase in R&D activities for the manufacturing of effective and safe therapeutics. Regarding this, the continuing studies on the preventing severe viral infections, such as the novel coronavirus, and those centered on the expansion of effective and safe vaccines have a positive impact on the industry.

The occurrence of hematological malignancies is increasing. As per the Leukemia & Lymphoma Society, every 3 minutes, a person is identified with leukemia, myeloma, or lymphoma in the U.S. Biopharma, for example gene, and immune cell therapies are quickly being accepted as a substitute treatment for hematological cancers. This is due to the fact that such therapeutics have high effectiveness and efficacy against these kinds of diseases.

The outsourcing category led the industry, with a 60% share, in 2022. This is due to the fact that outsourcing is becoming popular among small and medium-sized pharma firms because of the advantages provided to them.

Furthermore, for pharma firms, outsourcing surges therapeutic expertise and working efficiency, makes on demand services accessible, and assists in the development of their geographical presence.

Moreover, many small and medium-sized companies do not have the satisfactory resources for fulfilling their requirements for quality sterility testing and, consequently, desire outsourcing to pass FDA rules.

North America pharmaceutical sterility testing market had a major share of 40%, in 2022. This is credited to the presence of leading pharma and biopharma players, increasing R&D activities in the biotech and pharma industry, increasing number of product introductions, high occurrence of chronic ailments, and supportive policies of the government for the setup of R&D facilities.

Furthermore, the existence of strong healthcare policies, strict drug approval needs, increasing public consciousness of drug safety, increasing acceptance of pioneering technologies, and the launch of gene and cell therapies for treating more than a few hematologic malignancies are resultant in the development of the regional industry.

Furthermore, Europe follows North America in terms of revenue share. This is attributable to the formation of universal public healthcare systems in numerous nations in the region, which has considerably increased the requirement for healthcare products. The employment of stringent regulatory policies with regards to the safety of drugs is another key factor contributing to the growth of the industry.

The increasing acceptance of digital platforms has a positive impact on the demand for pharmaceutical sterility testing, and this will be the trend in the years to come as well.

Chapter 1. Research Scope

1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segments
- 1.4.1. Market size breakdown, by type
- 1.4.2. Market size breakdown, by product type
- 1.4.3. Market size breakdown, by test type
- 1.4.4. Market size breakdown, by application
- 1.4.5. Market size breakdown, by end user
- 1.4.6. Market size breakdown, by region
- 1.4.7. Market size breakdown, by country
1.5. Market Data Reporting Unit
- 1.5.1. Value
1.6. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research
- 2.1.1. Paid
- 2.1.2. Unpaid
- 2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

Chapter 6. Industry Outlook

6.1. Market Dynamics
- 6.1.1. Trends
- 6.1.2. Drivers
- 6.1.3. Restraints/challenges
- 6.1.4. Impact analysis of drivers/restraints
6.2. Impact of COVID-19
6.3. Porter's Five Forces Analysis
- 6.3.1. Bargaining power of buyers
- 6.3.2. Bargaining power of suppliers
- 6.3.3. Threat of new entrants
- 6.3.4. Intensity of rivalry
- 6.3.5. Threat of substitutes

Chapter 7. Global Market

7.1. Overview
7.2. Market Revenue, by Type (2017-2030)
7.3. Market Revenue, by Product type (2017-2030)
7.4. Market Revenue, by Test type (2017-2030)
7.5. Market Revenue, by Application (2017-2030)
7.6. Market Revenue, by End user (2017-2030)
7.7. Market Revenue, by Region (2017-2030)

Chapter 8. North America Market

8.1. Overview
8.2. Market Revenue, by Type (2017-2030)
8.3. Market Revenue, by Product type (2017-2030)
8.4. Market Revenue, by Test type (2017-2030)
8.5. Market Revenue, by Application (2017-2030)
8.6. Market Revenue, by End user (2017-2030)
8.7. Market Revenue, by Country (2017-2030)

Chapter 9. Europe Market

9.1. Overview
9.2. Market Revenue, by Type (2017-2030)
9.3. Market Revenue, by Product type (2017-2030)
9.4. Market Revenue, by Test type (2017-2030)
9.5. Market Revenue, by Application (2017-2030)
9.6. Market Revenue, by End user (2017-2030)
9.7. Market Revenue, by Country (2017-2030)

Chapter 10. APAC Market

10.1. Overview
10.2. Market Revenue, by Type (2017-2030)
10.3. Market Revenue, by Product type (2017-2030)
10.4. Market Revenue, by Test type (2017-2030)
10.5. Market Revenue, by Application (2017-2030)
10.6. Market Revenue, by End user (2017-2030)
10.7. Market Revenue, by Country (2017-2030)

Chapter 11. LATAM Market

11.1. Overview
11.2. Market Revenue, by Type (2017-2030)
11.3. Market Revenue, by Product type (2017-2030)
11.4. Market Revenue, by Test type (2017-2030)
11.5. Market Revenue, by Application (2017-2030)
11.6. Market Revenue, by End user (2017-2030)
11.7. Market Revenue, by Country (2017-2030)

Chapter 12. MEA Market

12.1. Overview
12.2. Market Revenue, by Type (2017-2030)
12.3. Market Revenue, by Product type (2017-2030)
12.4. Market Revenue, by Test type (2017-2030)
12.5. Market Revenue, by Application (2017-2030)
12.6. Market Revenue, by End user (2017-2030)
12.7. Market Revenue, by Country (2017-2030)

Chapter 13. U.S. Market

13.1. Overview
13.2. Market Revenue, by Type (2017-2030)
13.3. Market Revenue, by Product type (2017-2030)
13.4. Market Revenue, by Test type (2017-2030)
13.5. Market Revenue, by Application (2017-2030)
13.6. Market Revenue, by End user (2017-2030)

Chapter 14. Canada Market

14.1. Overview
14.2. Market Revenue, by Type (2017-2030)
14.3. Market Revenue, by Product type (2017-2030)
14.4. Market Revenue, by Test type (2017-2030)
14.5. Market Revenue, by Application (2017-2030)
14.6. Market Revenue, by End user (2017-2030)

Chapter 15. Germany Market

15.1. Overview
15.2. Market Revenue, by Type (2017-2030)
15.3. Market Revenue, by Product type (2017-2030)
15.4. Market Revenue, by Test type (2017-2030)
15.5. Market Revenue, by Application (2017-2030)
15.6. Market Revenue, by End user (2017-2030)

Chapter 16. France Market

16.1. Overview
16.2. Market Revenue, by Type (2017-2030)
16.3. Market Revenue, by Product type (2017-2030)
16.4. Market Revenue, by Test type (2017-2030)
16.5. Market Revenue, by Application (2017-2030)
16.6. Market Revenue, by End user (2017-2030)

Chapter 17. U.K. Market

17.1. Overview
17.2. Market Revenue, by Type (2017-2030)
17.3. Market Revenue, by Product type (2017-2030)
17.4. Market Revenue, by Test type (2017-2030)
17.5. Market Revenue, by Application (2017-2030)
17.6. Market Revenue, by End user (2017-2030)

Chapter 18. Italy Market

18.1. Overview
18.2. Market Revenue, by Type (2017-2030)
18.3. Market Revenue, by Product type (2017-2030)
18.4. Market Revenue, by Test type (2017-2030)
18.5. Market Revenue, by Application (2017-2030)
18.6. Market Revenue, by End user (2017-2030)

Chapter 19. Spain Market

19.1. Overview
19.2. Market Revenue, by Type (2017-2030)
19.3. Market Revenue, by Product type (2017-2030)
19.4. Market Revenue, by Test type (2017-2030)
19.5. Market Revenue, by Application (2017-2030)
19.6. Market Revenue, by End user (2017-2030)

Chapter 20. Japan Market

20.1. Overview
20.2. Market Revenue, by Type (2017-2030)
20.3. Market Revenue, by Product type (2017-2030)
20.4. Market Revenue, by Test type (2017-2030)
20.5. Market Revenue, by Application (2017-2030)
20.6. Market Revenue, by End user (2017-2030)

Chapter 21. China Market

21.1. Overview
21.2. Market Revenue, by Type (2017-2030)
21.3. Market Revenue, by Product type (2017-2030)
21.4. Market Revenue, by Test type (2017-2030)
21.5. Market Revenue, by Application (2017-2030)
21.6. Market Revenue, by End user (2017-2030)

Chapter 22. India Market

22.1. Overview
22.2. Market Revenue, by Type (2017-2030)
22.3. Market Revenue, by Product type (2017-2030)
22.4. Market Revenue, by Test type (2017-2030)
22.5. Market Revenue, by Application (2017-2030)
22.6. Market Revenue, by End user (2017-2030)

Chapter 23. Australia Market

23.1. Overview
23.2. Market Revenue, by Type (2017-2030)
23.3. Market Revenue, by Product type (2017-2030)
23.4. Market Revenue, by Test type (2017-2030)
23.5. Market Revenue, by Application (2017-2030)
23.6. Market Revenue, by End user (2017-2030)

Chapter 24. South Korea Market

24.1. Overview
24.2. Market Revenue, by Type (2017-2030)
24.3. Market Revenue, by Product type (2017-2030)
24.4. Market Revenue, by Test type (2017-2030)
24.5. Market Revenue, by Application (2017-2030)
24.6. Market Revenue, by End user (2017-2030)

Chapter 25. Brazil Market

25.1. Overview
25.2. Market Revenue, by Type (2017-2030)
25.3. Market Revenue, by Product type (2017-2030)
25.4. Market Revenue, by Test type (2017-2030)
25.5. Market Revenue, by Application (2017-2030)
25.6. Market Revenue, by End user (2017-2030)

Chapter 26. Mexico Market

26.1. Overview
26.2. Market Revenue, by Type (2017-2030)
26.3. Market Revenue, by Product type (2017-2030)
26.4. Market Revenue, by Test type (2017-2030)
26.5. Market Revenue, by Application (2017-2030)
26.6. Market Revenue, by End user (2017-2030)

Chapter 27. Saudi Arabia Market

27.1. Overview
27.2. Market Revenue, by Type (2017-2030)
27.3. Market Revenue, by Product type (2017-2030)
27.4. Market Revenue, by Test type (2017-2030)
27.5. Market Revenue, by Application (2017-2030)
27.6. Market Revenue, by End user (2017-2030)

Chapter 28. South Africa Market

28.1. Overview
28.2. Market Revenue, by Type (2017-2030)
28.3. Market Revenue, by Product type (2017-2030)
28.4. Market Revenue, by Test type (2017-2030)
28.5. Market Revenue, by Application (2017-2030)
28.6. Market Revenue, by End user (2017-2030)

Chapter 29. U.A.E. Market

29.1. Overview
29.2. Market Revenue, by Type (2017-2030)
29.3. Market Revenue, by Product type (2017-2030)
29.4. Market Revenue, by Test type (2017-2030)
29.5. Market Revenue, by Application (2017-2030)
29.6. Market Revenue, by End user (2017-2030)

Chapter 30. Competitive Landscape

30.1. List of Market Players and their Offerings
30.2. Competitive Benchmarking of Key Players
30.3. Product Benchmarking of Key Players
30.4. Recent Strategic Developments

Chapter 31. Company Profiles

31.1. Steris plc
- 31.1.1. Business overview
- 31.1.2. Product and service offerings
- 31.1.3. Key financial summary
31.2. Boston Analytical
- 31.2.1. Business overview
- 31.2.2. Product and service offerings
31.3. Sartorius AG
- 31.3.1. Business overview
- 31.3.2. Product and service offerings
31.4. Arbro Pharmaceuticals Private Limited & Auriga Research Private Limited
- 31.4.1. Business overview
- 31.4.2. Product and service offerings
31.5. Lucideon Limited
- 31.5.1. Business overview
- 31.5.2. Product and service offerings
31.6. Pace Analytical Life Sciences, LLC
- 31.6.1. Business overview
- 31.6.2. Product and service offerings
31.7. SGS SA
- 31.7.1. Business overview
- 31.7.2. Product and service offerings
- 31.7.3. Key financial summary
31.8. Sotera Health Company
- 31.8.1. Business overview
- 31.8.2. Product and service offerings
- 31.8.3. Key financial summary
31.9. Merck KGaA
- 31.9.1. Business overview
- 31.9.2. Product and service offerings
- 31.9.3. Key financial summary
31.10. Pall Corporation
- 31.10.1. Business overview
- 31.10.2. Product and service offerings
31.11. Charles River Laboratories International, Inc
- 31.11.1. Business overview
- 31.11.2. Product and service offerings
- 31.11.3. Key financial summary
31.12. Thermo Fisher Scientific Inc
- 31.12.1. Business overview
- 31.12.2. Product and service offerings
- 31.12.3. Key financial summary
31.13. Almac Group Limited
- 31.13.1. Business overview
- 31.13.2. Product and service offerings
31.14. Pacific BioLabs
- 31.14.1. Business overview
- 31.14.2. Product and service offerings
31.15. BIOMERIEUX S.A.
- 31.15.1. Business overview
- 31.15.2. Product and service offerings
- 31.15.3. Key financial summary

Chapter 32. Appendix

32.1. Abbreviations
32.2. Sources and References
32.3. Related Reports

한글목차

목차

제1장 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 업계 전문가/KOL의 소리

제5장 시장 지표

제6장 산업 전망

제7장 세계 시장

제8장 북미 시장

제9장 유럽 시장

제10장 아시아태평양 시장

제11장 중남미 시장

제12장 중동 및 아프리카 시장

제13장 미국 시장

제14장 캐나다 시장

제15장 독일 시장

제16장 프랑스 시장

제17장 영국 시장

제18장 이탈리아 시장

제19장 스페인 시장

제20장 일본 시장

제21장 중국 시장

제22장 인도 시장

제23장 호주 시장

제24장 한국 시장

제25장 브라질 시장

제26장 멕시코 시장

제27장 사우디아라비아 시장

제28장 남아프리카공화국 시장

제29장 아랍에미리트 시장

제30장 경쟁 상황

제31장 기업 개요